The PPARγ antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARγ-dependent and -independent mechanisms

Yekaterina Y. Zaytseva, Natalie K. Wallis, R. Chase Southard, Michael W. Kilgore

Research output: Contribution to journalArticlepeer-review

49 Scopus citations

Abstract

Background: Peroxisome proliferator-activated receptor gamma (PPARγ) is overexpressed in many types of cancer, including breast cancer, and it is regulated by ligand binding and post-translational modifications. It was previously demonstrated that endogenous transactivation promotes an aggressive phenotype of malignant breast cells. This study examines whether selective antagonism of PPARγ with T0070907 is a potential strategy for breast cancer therapy. Materials and Methods: PPARγ activation was inhibited using both pharmacological and molecular approaches and proliferation, apoptosis, migration and invasion were measured in MDA-MB-231 and MCF-7 breast cancer cells. Results: T0070907 treatment inhibited proliferation, invasion and migration but did not significantly affect apoptosis. Molecular inhibition using a dominant negative (Δ462) receptor yielded similar results. T007 also mediated a dose-dependent decrease in phosphorylation of PPARγ, and its ability to bind to DNA, and may directly affect mitogen-activated protein kinase signaling. Conclusion: These data indicate that inhibiting endogenous PPARγ signaling may be a promising new approach to breast cancer therapy.

Original languageEnglish
Pages (from-to)813-823
Number of pages11
JournalAnticancer Research
Volume31
Issue number3
StatePublished - Mar 2011

Keywords

  • Breast cancer
  • Invasion
  • Migration
  • PPARG
  • PPARγ
  • T0070907

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint

Dive into the research topics of 'The PPARγ antagonist T0070907 suppresses breast cancer cell proliferation and motility via both PPARγ-dependent and -independent mechanisms'. Together they form a unique fingerprint.

Cite this